Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +9.68% and -0.85%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?